A new study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and ...

offering new pathways for understanding and treating Duchenne Muscular Dystrophy (DMD). A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to ...

This year’s top stories on Duchenne muscular dystrophy (DMD) managed care included a novel imaging method for tracking disease progression, an FDA approval of the first nonsteroidal therapy ...

A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. McGill University researchers have discovered that an ...

Solid Biosciences ended Q3 2024 with $171.1 million in cash, securing operations through 2026. Initial Phase 1/2 trial results for SGT-003 in DMD expected in Q1 2025. Wedbush initiated coverage on ...

"The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD. This BLA is the culmination of a body of work that has been focused on bringing this potentially ...

There are currently no approved treatments for Becker, although Santhera Pharmaceuticals has been evaluating its approved Duchenne muscular dystrophy corticosteroid Agamree in an FDA-funded phase ...

European regulators are to review Sarepta Therapeutics’ Duchenne muscular dystrophy drug, eteplirsen – a drug that has sparked controversy in the US, where it was approved by the FDA against ...

Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it completed the submission of its Biologics License Application (BLA) for for ...